Prinomastat

DB05100InvestigationalSmall molecule

Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis,... As a lipophilic agent, prinomastat crosses the blood-brain barrier.

Primary indication: Investigated for use/treatment in brain cancer, lung cancer, and prostate cancer.Curator reviewed
Formula / weight: C₁₈H₂₁N₃O₅S₂ · 423.506 g/mol (avg)
Code names: AG-3340 · KB-R 9896

Resolves to

Compound

UNII10T6626FRKCAS192329-42-3ChEMBLCHEMBL75094ChEBI138885PubChem466151KEGGD03797

Structure

InChIKeyYKPYIPVDTNNYCN-INIZCTEOSA-NSMILESCC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)C1=CC=C(OC2=CC=NC=C2)C=C1

Targets

P09237MMP7P03956MMP1P08253MMP2

What you can answer from here — as of January 29, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Prinomastat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account